Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part A: Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part A: GMFR of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part A: GMT of SARS-CoV-2 Specific Binding Antibody (bAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part B: GMFR of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Part B: GMT of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Parts A and B: Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs);Parts A and B: Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Parts A and B: Number of Participants with Unsolicited Adverse Events (AEs)

Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part A: Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part A: GMFR of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part A: GMT of SARS-CoV-2 Specific Binding Antibody (bAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Part B: GMFR of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Part B: GMT of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29;Parts A and B: Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs);Parts A and B: Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Parts A and B: Number of Participants with Unsolicited Adverse Events (AEs)

Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;GMFR of SARS-CoV-2 Specific bAb Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;GMT of SARS-CoV-2 Specific Binding Antibody (bAb) Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs);Number of Participants With Seroresponse Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)

Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;GMFR of SARS-CoV-2 Specific bAb Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;GMT of SARS-CoV-2 Specific Binding Antibody (bAb) Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs);Number of Participants With Seroresponse Against Ancestral Strain of SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29;Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)